You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Anti-Fibrotic Therapy for Scleroderma/SSc

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, blood vessels, GI and kidney. Many patients who suffer from scleroderma/SSc also have a loss of pulmonary function. Scleroderma/SSc affects approximately 400,000 to 900,000 people in th ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Point of Care Detection of Respiratory Viruses

    SBC: LUCIGEN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): Respiratory infections have a significant health and economic impact worldwide. Current test products for the diagnosis of respiratory viral infections such as influenza are inadequate for the timely diagnosis needed for successful implementation of antiviral treatment. Unfortunately a test product that can accurately diagnose common respiratory viruses with hi ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Random Shear Shuttle BAC Libraries for Antimicrobial Discovery from Soil Metageno

    SBC: LUCIGEN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): 100,000 Americans perish each year due to untreatable bacterial infections. The societal benefits of new antibiotic compounds that are effective against numerous multiple drug resistant pathogens would be significant. The best possible source for new antibiotic structures with potentially novel mechanisms of action is within natural environments, particularly s ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Whole-brain fluorescence and brightfield imaging at single-cell level

    SBC: DMetrix, Inc            Topic: NIA

    DESCRIPTION (provided by applicant): The goal of this project is to develop an open and flexible imaging platform capable of rapid, 0.5- 5 m pixel resolution image capture of large-area histology sections (up to 125 mm by 175 mm), in brightfield and by epi-fluorescence optical sectioning. The project involves state-of-the- art instrumentation development coupled with application programming inter ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper

    SBC: Pulmokine, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with high morbidity and mortality. Signaling through the PDGFR leads to smooth muscle cell proliferation ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. SmartStop: Programmable Transdermal Nicotine Replacement Therapy

    SBC: CHRONO THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the Centers for Disease Control and Prevention, cigarette smoking causes the vast majority of lung cancers and over 400,000 deaths annually with a total monetary cost exceeding 190 billion. While the majority of the 45+ million US smokers want to quit, a small fraction of this number actually succeeds. The most popular smoking cessation products u ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Engineered tissue-based, high-throughput compound profiling

    SBC: Invivosciences, Inc.            Topic: 300

    DESCRIPTION provided by applicant Current NIGMS SBIR funding supported InvivoSciences LLCandapos s IVS launch of several product lines in IVS generated revenues from the sales of three dimensional D cell culture tools MC TM and IVS InsertsTM that can grow various hydrogel tissues without any support layers The culture tools enable Palpator TM and Tissue StretcherTM to stretch the ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Therapeutic for Liver Fibrosis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the treatment of liver fibrosis include changes in diet, life-style and/or medications to allevate the unde ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Engineered tissue-based, high-throughput compound profiling

    SBC: Invivosciences, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Current NIGMS-SBIR funding supported InvivoSciences LLC's (IVS) launch of several product lines in 2010. IVS generated revenues from the sales of three-dimensional (3D) cell culture tools (MC-8TM and IVS InsertsTM) thatcan grow various hydrogel tissues without any support layers. The culture tools enable Palpator TM and Tissue StretcherTM to stretch the hy ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Development of Non-compressible Hemostatic Agent for High-Volume Hemorrhage

    SBC: BIOMEDICA MANAGEMENT CORP.            Topic: NHLBI

    DESCRIPTION provided by applicant andquot ClotFoam R andquot is a novel adhesive sealant composition and second generation hemostatic agent This biological agent was designed to arrest moderate to severe blood loss arising from intracavitary traumatic injury or intraoperative hemorrhage without compression stitches or staples Control of Intraoperative hemorrhage in laparoscopic surgery whi ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government